Navigation Links
ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
Date:12/6/2010

SKILLMAN, N.J., Dec. 6, 2010 /PRNewswire/ -- ConvaTec Healthcare, a world-leading developer, manufacturer and marketer of innovative medical technologies for community and hospital care, today announced that in connection with a refinancing of its debt under its existing senior secured and mezzanine facilities and in combination with new senior secured credit facilities, it is offering $1,870,000,000 (equivalent) in Senior Secured Notes and Senior Notes. The offering of the new notes will not be registered under the Securities Act or any state securities laws and the new notes may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended and applicable state securities laws.

About ConvaTec ConvaTec is a leading developer and marketer of innovative medical technologies. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. From its operational headquarters in Skillman, New Jersey, the company conducts business in over 100 countries, serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements are all statements other than statements of historical facts. Certain of these forward looking statements are identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should," or "will" or the negative of such terms or other comparable terminology. Others can be identified from the context in which the statements are made. These statements involve a number of risks and uncertainties. Any forward-looking statements that we make herein and in future reports and statements are not guarantees of future performance, and actual results may differ materially from those in such forward-looking statements as a result of various factors relating to our strategy, outlook and growth prospects, including our operational and financial targets; the expected growth of the markets in which we operate; the competitive environment in which we operate; the economic outlook in general and, in particular, economic conditions in the European and U.S. markets; growth in demand for our products, increases in the penetration of our products into their respective markets, reimbursement rates for our products, or similar measures; and our expansion plans, including planned expansion into and growth in emerging markets; our ability to gain necessary regulatory approvals and desirable reimbursement rates for our newly developed products and technologies; and our ability to market and launch attractive new product designs and technologies. All forward-looking statements made in this press release are made as of the date hereof, and the risk that actual results will differ materially from expectations expressed herein will increase with the passage of time. The Company undertakes no duty to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

This announcement is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) (a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

In connection with the issuance of notes, the stabilizing manager may over-allot the notes or effect transactions with a view to supporting the market price of the notes, in each case at a level higher than that which might otherwise prevail.  However, there is no assurance that such stabilizing manager (or persons acting on behalf of such stabilizing manager) will undertake such stabilization actions.  Any stabilization action may begin on or after the date on which adequate public disclosure of the final terms of the offer of the notes is made and, if begun, may be ended at any time, but must end no later than the earlier of 30 calendar days after the issue date of the notes and 60 calendar days after the date of the allotment of the notes.

This document is an advertisement for purposes of applicable measures implementing Directive 2003/71/EC.

This announcement is not an offer to sell or the solicitation of an offer to buy the new notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful.Media ContactNimisha Savani908-904-2522Nimisha.savani@convatec.com
'/>"/>

SOURCE ConvaTec Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bradford Barton Named President, ConvaTec U.S.
2. ConvaTec to Present at AdvaMed 2010: The MedTech Conference
3. ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing
4. New Data Supports ConvaTec Negative Pressure Wound Therapy
5. Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps Access to Physicians
6. Masimo to Present at Piper Jaffray 22nd Annual Healthcare Conference
7. Prime Healthcare Converts System-Wide to Masimo rainbow SET Technology
8. Reportlinker Adds Healthcare Reform: 2010 Medical Device Industry Perceptions Survey
9. Crescent Healthcare Moves to CPR+ as Its Home Infusion Software Solution
10. Quest Diagnostics to Speak at the Lazard Capital Markets 7th Annual Healthcare Conference
11. Graymark Healthcare Reports Q3 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):